DJIA 15,973.84 313.66 2.00%
NASDAQ 4,337.51 70.68 1.66%
S&P 500 1,864.78 35.70 1.95%
market minute promo

Exelixis (NASDAQ: EXEL)

4.20 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

EXEL $4.20 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.33
Previous Close $4.20
Daily Range $4.01 - $4.33
52-Week Range $2.16 - $6.81
Market Cap $954.3M
P/E Ratio -4.62
Dividend (Yield) $0.00 (0.0%)
Volume 4,811,332
Average Daily Volume 4,883,476
Current FY EPS -$0.85




Drug Makers

Exelixis (EXEL) Description

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Website:

News & Commentary

Forget Gilead Sciences: These Stocks Doubled Last Year

Interested in stocks with huge growth potential? These three stocks hold promise for big gains in the years ahead.

Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study

Emotional Investing Deflates Exelixis, Inc. in January

Exelixis' fundamental thesis gets a lift in January, but that doesn't matter to skittish investors.

Exelixis Rises on Positive Late-Stage Trial Results

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis's Cabozantinib Granted Priority Review in the U.S.

Why Exelixis, Inc. Rocketed Higher on Friday

An upcoming catalyst gets amplified by the gyrating biotech sentiment.

'Mad Money' Lightning Round: Move on From Broadcom

Liking Exelixis And Its Pipeline - Cramer's Lightning Round (1/19/16)

Bristol-Myers Squibb: A New Chapter, and the Beginning of Sustained Growth

The tide is turning in a big way for Bristol-Myers Squibb, and CEO Giovanni Caforio let shareholders know about it during his presentation at the J.P. Morgan Healthcare Conference.

See More EXEL News...

EXEL's Top Competitors

EXEL $4.20 (0.00%)
Current stock: EXEL
TMO $126.48 (2.58%)
Current stock: TMO
ILMN $142.72 (3.08%)
Current stock: ILMN
WAT $118.41 (1.67%)
Current stock: WAT